Immunitybio Net Receivables vs Long Term Debt Analysis

IBRX Stock

USD 5.04 0.06 1.18%

Immunitybio financial indicator trend analysis is infinitely more than just investigating Immunitybio recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunitybio is a good investment. Please check the relationship between Immunitybio Net Receivables and its Long Term Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunitybio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Net Receivables vs Long Term Debt

Net Receivables vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunitybio Net Receivables account and Long Term Debt. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Immunitybio's Net Receivables and Long Term Debt is 0.11. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Immunitybio, assuming nothing else is changed. The correlation between historical values of Immunitybio's Net Receivables and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Immunitybio are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Net Receivables i.e., Immunitybio's Net Receivables and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.11

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Net Receivables

Long Term Debt

Long-term debt is a debt that Immunitybio has held for over one year. Long-term debt appears on Immunitybio balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Immunitybio balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from Immunitybio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunitybio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunitybio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.At this time, Immunitybio's Tax Provision is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 802.07 in 2024, whereas Selling General Administrative is likely to drop slightly above 91.7 M in 2024.

	2021	2023	2024 (projected)
Total Operating Expenses	331.2M	362.9M	218.0M
Cost Of Revenue	24.2M	18.5M	13.5M

Total Operating Expenses Cost Of Revenue

Immunitybio fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Common Stock Shares Outstanding
Total Assets		0.7	0.73	0.53	-0.38	0.71	-0.82	0.61	-0.75	0.64	0.75	0.88	0.42	0.93	0.23	0.76	0.58	0.69	0.81	0.68	0.71	0.95	0.45	0.57	0.7	0.63
Short Long Term Debt Total	0.7		0.8	0.73	-0.91	0.91	-0.57	0.97	-0.96	0.8	0.81	0.76	-0.16	0.52	0.05	0.98	0.87	0.97	0.93	0.98	0.95	0.57	0.6	0.72	0.95	0.83
Other Current Liab	0.73	0.8		0.7	-0.64	0.81	-0.72	0.83	-0.84	0.86	0.52	0.81	-0.11	0.53	0.28	0.74	0.59	0.76	0.83	0.75	0.75	0.58	0.59	0.38	0.78	0.72
Total Current Liabilities	0.53	0.73	0.7		-0.56	0.64	-0.43	0.8	-0.62	0.88	0.37	0.64	-0.14	0.35	0.0	0.67	0.3	0.75	0.58	0.6	0.65	0.4	0.98	0.45	0.51	0.42
Total Stockholder Equity	-0.38	-0.91	-0.64	-0.56		-0.8	0.28	-0.91	0.86	-0.64	-0.66	-0.53	0.44	-0.18	0.03	-0.85	-0.87	-0.87	-0.77	-0.92	-0.85	-0.24	-0.44	-0.64	-0.87	-0.82
Property Plant And Equipment Net	0.71	0.91	0.81	0.64	-0.8		-0.77	0.9	-0.96	0.79	0.71	0.88	-0.12	0.45	0.26	0.93	0.82	0.94	0.96	0.92	0.98	0.51	0.51	0.78	0.92	0.84
Current Deferred Revenue	-0.82	-0.57	-0.72	-0.43	0.28	-0.77		-0.53	0.72	-0.6	-0.52	-0.87	-0.27	-0.65	-0.45	-0.64	-0.49	-0.62	-0.81	-0.57	-0.69	-0.69	-0.32	-0.57	-0.65	-0.58
Net Debt	0.61	0.97	0.83	0.8	-0.91	0.9	-0.53		-0.93	0.86	0.65	0.75	-0.23	0.38	0.04	0.92	0.78	0.96	0.88	0.93	0.92	0.44	0.68	0.66	0.89	0.81
Retained Earnings	-0.75	-0.96	-0.84	-0.62	0.86	-0.96	0.72	-0.93		-0.78	-0.8	-0.84	0.1	-0.54	-0.17	-0.96	-0.9	-0.95	-0.99	-0.97	-0.96	-0.6	-0.47	-0.75	-0.98	-0.89
Accounts Payable	0.64	0.8	0.86	0.88	-0.64	0.79	-0.6	0.86	-0.78		0.42	0.82	-0.05	0.38	0.05	0.72	0.47	0.85	0.75	0.71	0.75	0.45	0.81	0.56	0.69	0.61
Cash	0.75	0.81	0.52	0.37	-0.66	0.71	-0.52	0.65	-0.8	0.42		0.58	0.07	0.74	0.07	0.86	0.86	0.74	0.81	0.85	0.78	0.76	0.24	0.66	0.84	0.65
Non Current Assets Total	0.88	0.76	0.81	0.64	-0.53	0.88	-0.87	0.75	-0.84	0.82	0.58		0.21	0.64	0.29	0.79	0.6	0.83	0.87	0.74	0.84	0.69	0.55	0.72	0.75	0.76
Non Currrent Assets Other	0.42	-0.16	-0.11	-0.14	0.44	-0.12	-0.27	-0.23	0.1	-0.05	0.07	0.21		0.52	0.18	-0.06	-0.1	-0.09	0.02	-0.13	-0.11	0.49	-0.14	0.02	-0.1	-0.25
Cash And Short Term Investments	0.93	0.52	0.53	0.35	-0.18	0.45	-0.65	0.38	-0.54	0.38	0.74	0.64	0.52		0.14	0.6	0.46	0.46	0.62	0.51	0.48	1.0	0.28	0.35	0.54	0.41
Net Receivables	0.23	0.05	0.28	0.0	0.03	0.26	-0.45	0.04	-0.17	0.05	0.07	0.29	0.18	0.14		0.12	0.1	0.09	0.23	0.09	0.2	0.16	-0.05	0.01	0.12	0.04
Common Stock Total Equity	0.76	0.98	0.74	0.67	-0.85	0.93	-0.64	0.92	-0.96	0.72	0.86	0.79	-0.06	0.6	0.12		0.89	0.96	0.94	0.98	0.97	0.64	0.54	0.78	0.94	0.83
Non Current Liabilities Total	0.58	0.87	0.59	0.3	-0.87	0.82	-0.49	0.78	-0.9	0.47	0.86	0.6	-0.1	0.46	0.1	0.89		0.82	0.87	0.94	0.87	0.5	0.14	0.7	0.95	0.83
Other Current Assets	0.69	0.97	0.76	0.75	-0.87	0.94	-0.62	0.96	-0.95	0.85	0.74	0.83	-0.09	0.46	0.09	0.96	0.82		0.92	0.95	0.97	0.52	0.63	0.83	0.91	0.81
Other Stockholder Equity	0.81	0.93	0.83	0.58	-0.77	0.96	-0.81	0.88	-0.99	0.75	0.81	0.87	0.02	0.62	0.23	0.94	0.87	0.92		0.94	0.95	0.67	0.43	0.75	0.97	0.84
Total Liab	0.68	0.98	0.75	0.6	-0.92	0.92	-0.57	0.93	-0.97	0.71	0.85	0.74	-0.13	0.51	0.09	0.98	0.94	0.95	0.94		0.96	0.56	0.46	0.75	0.98	0.85
Property Plant And Equipment Gross	0.71	0.95	0.75	0.65	-0.85	0.98	-0.69	0.92	-0.96	0.75	0.78	0.84	-0.11	0.48	0.2	0.97	0.87	0.97	0.95	0.96		0.54	0.52	0.81	0.93	0.84
Total Current Assets	0.95	0.57	0.58	0.4	-0.24	0.51	-0.69	0.44	-0.6	0.45	0.76	0.69	0.49	1.0	0.16	0.64	0.5	0.52	0.67	0.56	0.54		0.33	0.4	0.58	0.47
Short Term Debt	0.45	0.6	0.59	0.98	-0.44	0.51	-0.32	0.68	-0.47	0.81	0.24	0.55	-0.14	0.28	-0.05	0.54	0.14	0.63	0.43	0.46	0.52	0.33		0.36	0.35	0.31
Intangible Assets	0.57	0.72	0.38	0.45	-0.64	0.78	-0.57	0.66	-0.75	0.56	0.66	0.72	0.02	0.35	0.01	0.78	0.7	0.83	0.75	0.75	0.81	0.4	0.36		0.72	0.7
Common Stock	0.7	0.95	0.78	0.51	-0.87	0.92	-0.65	0.89	-0.98	0.69	0.84	0.75	-0.1	0.54	0.12	0.94	0.95	0.91	0.97	0.98	0.93	0.58	0.35	0.72		0.87
Common Stock Shares Outstanding	0.63	0.83	0.72	0.42	-0.82	0.84	-0.58	0.81	-0.89	0.61	0.65	0.76	-0.25	0.41	0.04	0.83	0.83	0.81	0.84	0.85	0.84	0.47	0.31	0.7	0.87

Click cells to compare fundamentals

Immunitybio Account Relationship Matchups

Immunitybio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	143.1M	221.4M	468.9M	362.4M	504.5M	288.0M
Short Long Term Debt Total	14.8M	275.5M	645.7M	723.8M	726.7M	763.1M
Other Current Liab	5.8M	51.6M	52.3M	45.3M	43.8M	25.3M
Total Current Liabilities	11.6M	68.1M	369.0M	500.9M	58.3M	108.2M
Total Stockholder Equity	120.7M	(119.8M)	(242.2M)	(447.3M)	(587.0M)	(557.6M)
Property Plant And Equipment Net	72.2M	90.7M	119.2M	189.4M	182.7M	191.8M
Net Debt	(660K)	240.6M	464.6M	619.1M	461.3M	484.3M
Retained Earnings	(662.2M)	(1.6B)	(2.0B)	(2.4B)	(3.0B)	(2.8B)
Accounts Payable	1.7M	11.5M	11.4M	21.0M	9.2M	7.2M
Cash	15.5M	34.9M	181.1M	104.6M	265.5M	278.7M
Non Current Assets Total	87.4M	109.7M	134.6M	221.8M	210.4M	115.9M
Non Currrent Assets Other	(11.1M)	3.3M	7.2M	6.6M	9.7M	15.6M
Cash And Short Term Investments	51.7M	96.1M	317.1M	107.2M	266.5M	159.3M
Net Receivables	303K	2.0M	1.3M	1.9M	3.2M	2.7M
Common Stock Total Equity	10K	11K	40K	42K	48.3K	50.7K
Liabilities And Stockholders Equity	143.1M	221.4M	468.9M	362.4M	504.5M	288.0M
Non Current Liabilities Total	10.9M	271.7M	343.8M	311.3M	1.0B	1.1B
Other Current Assets	3.8M	9.2M	15.9M	31.5M	24.5M	25.7M
Other Stockholder Equity	783.0M	1.5B	1.7B	1.9B	2.4B	2.5B
Total Liab	22.4M	339.9M	712.8M	812.2M	1.1B	1.1B
Property Plant And Equipment Gross	72.2M	67.4M	172.2M	258.7M	267.0M	280.4M
Total Current Assets	55.8M	111.7M	334.3M	140.6M	294.1M	172.1M
Accumulated Other Comprehensive Income	(105K)	122K	4K	183K	10K	10.5K
Intangible Assets	12.1M	1.5M	1.4M	20.0M	17.1M	17.9M
Common Stock	10K	38K	40K	42K	67K	70.4K
Short Term Investments	36.1M	61.1M	136.0M	2.5M	1.0M	958.5K
Other Assets	1.0	7.6M	6.4M	6.6M	7.6M	4.4M
Capital Surpluse	783.0M	1.5B	1.7B	1.9B	2.2B	1.3B
Property Plant Equipment	27.8M	29.0M	82.9M	143.7M	165.2M	173.5M
Other Liab	8.3M	1.6M	411K	22.0M	25.3M	26.6M
Net Tangible Assets	(118.6M)	(236.5M)	(243.6M)	(467.3M)	(420.6M)	(399.6M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunitybio Net Receivables vs Long Term Debt Analysis

Net Receivables vs Long Term Debt

Net Receivables vs Long Term Debt Correlation Analysis

Correlation Coefficient

Net Receivables

Long Term Debt

Immunitybio fundamental ratios Correlations

Immunitybio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunitybio fundamental ratios Accounts

Also Currently Popular

Additional Tools for Immunitybio Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock Total Equity	+ 0.98	Short Long Term Debt Total
Total Liab	+ 0.98	Short Long Term Debt Total
Short Term Debt	+ 0.98	Total Current Liabilities
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Total Liab	+ 0.98	Common Stock Total Equity

Other Stockholder Equity	- 0.99	Retained Earnings
Common Stock	- 0.98	Retained Earnings
Total Liab	- 0.97	Retained Earnings
Property Plant And Equipment Gross	- 0.96	Retained Earnings
Common Stock Total Equity	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Property Plant And Equipment Net